Discontinued — last reported Q2 '23
Year-over-year, this metric declined by 100.0%, from $29.00M to $0.00.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $714.01M | $55.65M | $512.18M | $0.00 | $32.65M | $5.05M | -$315.00K | $0.00 | $219.00M | $956.00M | $6.00M | $29.00M | $0.00 | $40.00M | $0.00 | $0.00 |
| QoQ Change | — | — | -92.2% | +820.4% | -100.0% | — | -84.5% | -106.2% | +100.0% | — | +336.5% | -99.4% | +383.3% | -100.0% | — | -100.0% | — |
| YoY Change | — | — | — | — | — | -95.4% | -90.9% | -100.1% | — | +570.7% | >999% | >999% | — | -100.0% | -95.8% | -100.0% | -100.0% |